Marzetti (MZTI) Q4 2026 Earnings Call Transcript

Marzetti reported FY2026 record results: Q4 consolidated net sales fell 2.2% to $465.0M, but adjusted EPS rose 9.0% to $1.46 (reported EPS $1.76 including a $0.66 facility-sale gain). Q4 gross margin expanded 220 bps YoY to 24.5% and adjusted operating income grew 17.5% to $52.2M, supported by productivity and cost savings. For FY2027, management guided mid-single-digit revenue growth and ~100 bps gross margin expansion, but warned Q1 operating income may decline ~15% due to a Cyclospora-related volume headwind (~250 bps net sales impact) while commodity inflation is forecast at ~5% to be offset by pricing/cost actions.

Analysis

This reads like a classic “good business, bad quarter” setup: the market will likely anchor on the next 30-60 days of interrupted volume, but the more important variable is whether Marzetti can keep translating mix and procurement into margin while the transitory shock burns off. The key second-order effect is that the outbreak is hitting the very part of the portfolio where gross margin leverage is usually highest, so the near-term EPS hit will look worse than the revenue hit and can create an overreaction in the multiple.

Over 1-3 months, the main catalyst is not the recovery itself but proof that the reset in household demand is following the usual half-life and that the new product pipeline is still gaining distribution. If Bachan’s trial moves meaningfully above the current low-single-digit penetration, the market will start capitalizing it as a platform asset rather than a one-off acquisition. If that trial stalls, the stock becomes a leverage story without enough organic growth to justify a premium.

The contrarian view is that consensus may be underestimating how much pricing power exists in a branded, shelf-stable portfolio with improving logistics, while overestimating the durability of the outbreak drag. The real risk is a Q2/Q3 “recovery that never fully inflects” if pantry demand softens, the club channel remains weak, or retailer resets push the new launches into a crowded shelf set. The stock should be falsified if the expected margin rebound does not show up by mid-year or if management is forced to revisit the 100 bp gross margin expansion target.

Key Decisions for Investors

• Buy MZTI on any 5-8% post-earnings drawdown; target a 3-6 month rebound as the outbreak lap clears and Bachan’s distribution expands. Risk/reward favors long exposure only after the market has priced the Q1 profit air pocket.
• Pair trade: long MZTI / short GIS for 6 months. MZTI has a clearer self-help margin path and acquisition-led growth, while GIS is more exposed to sluggish category volume and less incremental operating leverage.
• Set a hard watch item on MZTI: if Bachan’s household penetration is still stuck below 7% by the next two updates, treat the acquisition as a marketing spend story rather than a growth engine and de-rate the stock.
• Use TXRH as a secondary read-through only, not a standalone trade: if the licensed roll platform keeps taking share, it supports the brand halo, but the economics are too small to move TXRH meaningfully absent broader restaurant data.